Skip to content

Study · Non-randomized trial · n = 33 · 2013

1 result

A single histrelin implant is effective for 2 years for treatment of central precocious puberty.

Lewis KA, Goldyn AK, West KW, Eugster EA

The Journal of pediatrics1 Jul 2013Cited by 43 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In 33 children with CPP, a histrelin implant produced equivalent pubertal suppression at 12 and 24 months.

    In plain wordsIn children with CPP, histrelin suppressed puberty equally at 12 and 24 months.

    Peptide
    Histrelin
    Outcome
    No significant changePubertal suppression at 24 months
    Study

    n = 33

    Comparator
    12-month assessment in the same children
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Equivalent suppression was observed when comparing 12 and 24 months in 33 children with central precocious puberty.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.